會員中心
新冠研究蛋白、抗體等試劑庫
發(fā)布時間：2022-06-15 16:16:45 點(diǎn)擊：3011
新冠研究蛋白、抗體等試劑庫
由新冠病毒引起的新冠肺炎疫情影響了全球的醫(yī)療衛(wèi)生系統(tǒng)以及經(jīng)濟(jì)，同時不斷突變的新毒株對新冠疫苗、治療藥物以及診斷都帶來了巨大的挑戰(zhàn)。義翹神州一直密切關(guān)注新冠病毒的進(jìn)化情況，已保證第一時間研發(fā)出新冠病毒相關(guān)的蛋白、抗體等試劑。目前，我們的蛋白、抗體試劑以廣泛被全球科學(xué)家們用于新冠相關(guān)的各方面的研究，已助力正式發(fā)表900多篇科研論文。除此之外，我們的試劑產(chǎn)品也被用于免疫檢測試劑的核心原料用于其開發(fā)上市。我們已開發(fā)了擁有200+新冠突變體蛋白的突變體蛋白庫，覆蓋了VOC, VOI等突變位點(diǎn)。這些突變體蛋白也已經(jīng)被研究著們用于新冠病毒免疫逃逸等相關(guān)研究。
重組新冠抗原
重組Spike蛋白
重組N蛋白
重組突變體蛋白庫
酶類，NSP蛋白等
宿主受體ACE2蛋白
SARS-CoV-2 Spike 蛋白推薦
| 貨號 | 抗原 | 表達(dá)宿主 | 標(biāo)簽 |
| 40591-V08H | S1 | HEK293 Cells | His |
| 40590-V08B | S2 | Baculovirus-Insect Cells | His |
| 40592-V05H | RBD | HEK293 Cells | mFc |
| 40592-V08B | RBD | Baculovirus-Insect Cells | His |
| 40592-V08H | RBD | HEK293 Cells | His |
更多SARS-CoV-2 Spike 蛋白
| 貨號 | 抗原 | 表達(dá)宿主 | 標(biāo)簽 |
| 40589-V08H4 | S1+S2 ECD | HEK293 Cells | His |
| 40591-V02H | S1 | HEK293 Cells | Fc |
| 40591-V05H1 | S1 | HEK293 Cells | mFc |
| 40591-V08B1 | S1 | Baculovirus-Insect Cells | His |
| 40591-V08H-B Biotinylated | S1 | HEK293 Cells | His |
| 40591-V27H-B Biotinylated | S1 | HEK293 Cells | AVI & His |
| 40591-V41H | S1 NTD | HEK293 Cells | Fc & AVI |
| 40591-V41H-B Biotinylated | S1 NTD | HEK293 Cells | Fc & AVI |
| 40591-V49H | S1 NTD | HEK293 Cells | His & AVI |
| 40591-V49H-B Biotinylated | S1 NTD | HEK293 Cells | His & AVI |
| 40589-V08B1 | S1+S2 ECD | Baculovirus-Insect Cells | His |
| 40589-V08B1-B Biotinylated | S1+S2 ECD | Baculovirus-Insect Cells | His |
| 40589-V27B-B Biotinylated | S1+S2 ECD | Baculovirus-Insect Cells | AVI & His |
| 40590-V02H | S2 | HEK293 Cells | Fc |
| 40590-V05B | S2 | Baculovirus-Insect Cells | mFc |
| 40590-V08B-B Biotinylated | S2 | Baculovirus-Insect Cells | His |
| 40590-V08H1 | S2 | HEK293 Cells | His |
| 40592-V02H | RBD | HEK293 Cells | Fc |
| 40592-V08B-B Biotinylated | RBD | Baculovirus-Insect Cells | His |
| 40592-V08H-B Biotinylated | RBD | HEK293 Cells | His |
| 40592-V27B-B Biotinylated | RBD | Baculovirus-Insect Cells | AVI & His |
| 40592-V27H-B Biotinylated | RBD | HEK293 Cells | AVI & His |
| 40592-V31H | RBD | HEK293 Cells | rFc |
| 40592-VNAH | RBD | HEK293 Cells |
新冠抗體試劑
義翹神州開發(fā)生產(chǎn)了針對新冠病毒不同抗原抗體試劑，特異性、中和效應(yīng)以及多種應(yīng)用均經(jīng)過驗(yàn)證。
高親和力
Binding affinity has been validated by BLI assay.
BLI: KD=0.006 nM
Anti-Spike Rabbit MAb (cat#:40592-R001)
BLI: KD=0.01 nM
Anti-N Rabbit MAb (cat#:40143-R040)
高特異性
ELISA assay has been taken to validate the cross-reactivity with Spike antigens from different Human Coronaviruses.
No cross-reactivity with SARS-CoV, MERS-CoV, HKU1, 229E, NL63, and OC43.
中和效應(yīng)
The anti-RBD neutralizing antibody could effectively block the binding between recombinant spike RBD and ACE2 protein, and inhibit the infection of spike pseudovirus to ACE2 overexpressed HEK293T cells.
Anti-Spike RBD Mouse MAb (cat#: 40592-MM57)
 |  |  |
試劑盒采用雙抗夾心ELISA法，可以快速定量檢測N蛋白和S蛋白。試劑盒中使用的抗體均為義翹神州自主研發(fā)生產(chǎn)的單克隆抗體，已實(shí)現(xiàn)大量生產(chǎn)且可保證批次間穩(wěn)定性。其中，S試劑盒經(jīng)過重組蛋白和假病毒檢測雙重驗(yàn)證。 | SARS-CoV-2 N Detection Kit (KIT40588)  | |
| 更多詳情：新冠病毒抗原蛋白檢測試劑盒 | ||
| ? 新冠病毒抑制劑篩選試劑盒 ? 新冠病毒抗體滴度檢測試劑盒 | ||
新冠試劑發(fā)表文獻(xiàn)
截止到4月30日，已有近500篇正式發(fā)表的文章以及120篇預(yù)發(fā)表文章引用了義翹神州開發(fā)的新冠相關(guān)科研試劑。
| 題目 | 期刊 | 作者 | 年份 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity | Cell | Thomson, E,et al. | 2021 |
| Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection | Cell | Brouwer, PJM,et al. | 2021 |
| The antigenic anatomy of SARS-CoV-2 receptor binding domain | Cell | Dejnirattisai, W,et al. | 2021 |
| BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection | Cell | Mills, R,et al. | 2021 |
| COVID-19 immune features revealed by a large-scale single cell transcriptome atlas | Cell | Ren, X,et al. | 2021 |
| Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia | Cell | Asarnow, D,et al. | 2021 |
| Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\' B cells | Cell | Cao, Y,et al. | 2020 |
| Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies | Cell | Wrapp, Daniel,et al. | 2020 |
| Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment | Cell | Sun, J,et al. | 2020 |
| Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 | Cell | Wang, H,et al. | 2020 |
| A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS | Cell | Dai, L,et al. | 2020 |
| The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity | Cell | Li, Q,et al. | 2020 |
| A thermostable mRNA vaccine against COVID-19 | Cell | Zhang, N,et al. | 2020 |
| High potency of a bivalent human VH domain in SARS-CoV-2 animal models | Cell | Li, W,et al. | 2020 |
| Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology | Cell | Piccoli, L,et al. | 2020 |
| Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant | Cell | Yurkovetskiy, L,et al. | 2020 |
| Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy | Cell | Du, S,et al. | 2020 |
| Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19 | Cell | Meckiff, B,et al. | 2020 |
| Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production | Cell | Chen, Y,et al. | 2020 |
| Compromised humoral functional evolution tracks with SARS-CoV-2 mortality | Cell | Zohar, T,et al. | 2020 |
| A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 | Cell | Hassan, AO,et al. | 2020 |
| Compromised SARS-CoV-2-specific placental antibody transfer | Cell | Atyeo, C,et al. | 2020 |
2019新型冠狀病毒，即"SARS-CoV-2 (2019-nCoV)"，因2019年武漢病毒性肺炎病例而被發(fā)現(xiàn)，和2003年的 SARS冠狀病毒以及2012年的MERS冠狀病毒同屬于冠狀病毒科β屬。
冠狀病毒基因組依次編碼棘突蛋白(spike protein)、包膜蛋白(Envelope protein)、膜蛋白(Membrane protein)和核衣殼蛋白(Nucleocapsid)。
棘突蛋白(spike protein) 是冠狀病毒最重要的表面膜蛋白，含有兩個亞基（subunit）， S1和S2。其中S1主要包含有受體結(jié)合區(qū)（receptorbinding domain， RBD），負(fù)責(zé)識別細(xì)胞的受體。S2含有膜融合過程所需的基本元件。
Spike 蛋白承擔(dān)病毒與宿主細(xì)胞膜受體結(jié)合及膜融合功能，是宿主中和抗體的重要作用位點(diǎn)以及疫苗設(shè)計的關(guān)鍵靶點(diǎn)。SARS-CoV-2 (2019-nCoV) 的Spike蛋白與人ACE2互作來感染人的呼吸道上皮細(xì)胞。
核衣殼蛋白是冠狀病毒中含量最豐富的蛋白。在病毒體組裝過程中，N蛋白與病毒RNA結(jié)合并導(dǎo)致螺旋核衣殼的形成。核衣殼蛋白是一種高度免疫原性的磷蛋白，與病毒基因組復(fù)制和調(diào)節(jié)細(xì)胞信號通路有關(guān)。由于N蛋白的序列保守性和強(qiáng)大的免疫原性，N蛋白常被作為冠狀病毒診斷檢測工具
義翹神州于1月22日全球首發(fā)新冠病毒（SARS-CoV-2）重要靶點(diǎn)Spike RBD重組蛋白。為了更好的支持新冠肺炎的研究，義翹神州開發(fā)生產(chǎn)了數(shù)百種新冠病毒（SARS-CoV-2）相關(guān)科研試劑，包括抗原蛋白（N蛋白、Spike全長胞外域、 Spike S1、Spike S2、Spike RBD, Plpro, MTase, NSP3, NSP8，NSP9）、單抗、抗原蛋白檢測試劑盒、抑制劑篩選試劑盒、抗體滴度檢測試劑盒以及即用型表達(dá)基因。這些科研試劑已被全球數(shù)百家研究機(jī)構(gòu)用于疫苗和治療性抗體開發(fā)。義翹神州還可以提供新冠假病毒中和檢測服務(wù)，可用于篩選出具有中和活性的抗體或血清，支持藥物研發(fā)在細(xì)胞水平上的評估。
SARS-CoV-2 (2019-nCoV)抗原試劑產(chǎn)品列表
引用文獻(xiàn)
? Xintian Xu.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.SCIENCE CHINA Life Sciences.2020
? Bo Diao, Zeqing Feng.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv preprint
